ICS Developers
ShapeTX CEO Francois Vigneault Says Generative AI Will Drive Programmable RNA Medicines, Enabling Targeted, Durable Therapies
ShapeTX CEO Francois Vigneault discusses using generative AI to design programmable RNA medicines that repair disease-causing genetic mutations, aiming to make treatments faster, more targeted, and less costly. The conversation covers differences from CRISPR and mRNA vaccines, AI-driven drug discovery, targeted AAV delivery to reduce side effects, and durable RNA editing outcomes.